Irbesartan and Oseltamivir treatment of COVID-19 infection.
Phase 1
- Conditions
- The combined treatment in this trial will be used to treat patients with Covid-19 infection in order to prevent the patients need for further treatment in a hospital.MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2020-001610-38-DK
- Lead Sponsor
- Slagelse Sygehus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Patients age 50-89 years and Covid-19 positiv and home.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 40
Exclusion Criteria
Actual treatment with ACE-inhibitor, AT-II receptor antagonist or diuretics
Blood pressure below 110/60
Pregnancy
Allergy to Irbesartan or Oseltamivir
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method